Abstract:Objective To explore the effects of moderate-intensity aerobic exercise(MIAE)and dexrazoxane(DEX)on rats myocardial damage induced by epirubicin.Methods A total of 40 SD female rats were randomly divided into normal control group(n=8)and myocardial injury group(n=32)to establish the rats myocardial damage model-induced by epirubicin. After successful modeling,the myocardial injury group was randomly divided into four groups:model group,DEX group,moderate-intensity aerobic exercise(MIAE)group and dexrazoxane plus moderate-intensity aerobic exercise(DEX+MIAE)group,and each group was treated for six weeks. Catalase(CAT),total superoxide dismutase(T-SOD),malondialdehyde(MDA)and apoptotic myocardial cell index were measured and the ventricular tissue was also pathological examined.Results After six weeks intervention,the level of CAT in the DEX+MIAE group was lower than that in the normal control group,but was higher than that in the DEX group,the MIAE group and the model group(P<0.05);the DEX+MIAE group was lower than the normal control group,but was higher than the DEX group,the MIAE group and the model group in the level of the T-SOD(P<0.05);the DEX+MIAE group was lower than the DEX group,the MIAE group and the model group(P<0.05),but there was no significant difference compared with the normal control group in the level of the MDA(P>0.05). The myocardial cell pathology score and the apoptotic index in the DEX+MIAE group was lower than those in the model group(P<0.01),but there was no significant difference compared with the normal control group (P>0.01). The degree of myocardial cell damage in the DEX+MIAE group was the lightest when observed by light microscope.Conclusion MIAE can improve the activity of CAT and T-SOD,reduce the level of MDA and the production of oxygen free radicals,also protect the cardiomyocytes. MIAE can improve the therapeutic effect of DEX.
[1] CARVALHO F S,BURGEIRO A,GARCIA R,et al.Doxorubicin-induced cardiotoxicity:from bioenergetic failure and cell death to cardiomyopathy[J]. Med Res Rev,2014,34(1):106-135. [2] SMITH L A,CORNERLIUS V R,PLUMMER C J,et al.Cardiotoxicity of anthracycline agents for the treatment of cancer:systematic review and meta-analysis of randomised controlled trials[J]. BMC Cancer,2010,10:337. [3] SZMIT S,JURCZAK W,ZAUCHA J M,et al. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders[J]. Int J Cardiol,2017,235:147-153. [4] SETHI T K,BASDAG B,BHATIA N,et al. Beyond anthracyclinese:preemptive management of cardiovascular toxicity in the era of targeted agents for hematologic malignancies[J]. Curr Hemato Malig Rep,2017,12(3):257-267. [5] WERNER C,HANHOUN M,WIDMANN T,et al. Effects of physical exercise on myocardial telomere-regulating proteins,survival pathways,and apoptosis[J]. J Am Coll Cardiol,2008, 52(6):470-482. [6] 吴晖,欧阳取长,刘莉萍,等. 右丙亚胺对表柔比星诱导大鼠心肌损伤干预机制研究[J]. 中华肿瘤防治杂志,2013,20(19):1473-1477. [7] KWOK J C,RICHARDSON D R. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells:inhibition of the ferritin iron mobilization pathway[J]. Mol Pharmacol,2003,63(4):849-861. [8] STĚRBA M,POPELOVÁ O,VÁVROVÁ A,et al. Oxidative stress,redox signaling,and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection[J]. Antioxid Redox Signal,2013,18(8):899-929. [9] 赵楚敏,赵刚,王,等. 右丙亚胺对表阿霉素化疗的老年乳腺癌患者心脏保作用的研究[J]. 中国心血管病研究杂志,2014,12(5):475-478. [10] JIRKOVSKY E,LENCOVá-POPELOVÁ O,HROCH M,et al.Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits[J]. Toxicology,2013,311(3):191- 204. [11] GROVER S,LEONG D P,CHAKRABARTY A,et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy:a prospective study using novel cardiac imaging and biochemical markers[J]. Int J Cardiol,2013,168(6):5465- 5467. [12] 吴晖,欧阳取长,刘莉萍,等. 右丙亚胺对表柔比星致大鼠心肌损伤的保护作用及机制研究[J]. 肿瘤药学,2014,4(1):40-45. [13] VAN DALEN E,CARON H,DICKINSON H,et a1. Cardioprotective interventions for cancer patients receiving anthracyclines[J].Cochrane Db Syst Rev,2011,6:3917. [14] MARTY M,ESPIÉ M,LLOMBART A,et al. Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy[J]. Ann Oncol,2006,17(4):614-622. [15] 俞志红,朱利月,周欢琴. 规律有氧运动对原发性高血压患者动脉弹性的影响[J]. 浙江预防医学,2016,28(3):240-243. [16] ZHANG S,LIU X,BAWA-KHALFE T,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med,2012,18(11):1639-1642. [17] 王雁,王伯忠,项巧珍,等. 高强度运动对高同型半胱氨酸血症大鼠抗氧化和内皮功能的影响[J]. 预防医学,2017,29(6):550-554.